ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Brii Bio Receives the BioCentury-BayHelix R&D Achievement of the Year Award at the 2021 BioCentury China Healthcare Summit
November 18, 2021Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens... -
NIH trial closes enrolment for Brii Biosciences’ Covid-19 antibodies
August 06, 2021Brii Biosciences has reported that the National Institutes of Health (NIH)’s ACTIV-2 clinical trial in the US completed enrolment for the Phase III part assessing its combination treatment, BRII-196 plus BRII-198, for Covid-19. -
US closes enrolment in two COVID-19 antibody studies due to futility
March 08, 2021The sub-studies evaluating VIR-7831 and BRII-196 with BRII-198 have stopped enrolment based on recommendations from the Data and Safety Monitoring Board. -
Trial to evaluate monoclonal antibody therapy for mild-to-moderate COVID-19
January 07, 2021The study will determine if the combination of BRII-196 and BRII-198, two investigational antibodies for SARS-CoV-2, can prevent disease progression.
Pharma Sources Insight January 2025
